CSL partners with Alentis Therapeutics to co-develop lixudebart, while Jiangsu Nhwa licenses a clinical-stage sleep disorder candidate to Somnivera.
|Articles|June 25, 2015
Outlook: Market Access in Australia
Despite recent challenges, the Australian market still offers a number of opportunities for pharma manufacturers.
Advertisement
Australia is a country that has challenged pharmaceutical manufacturers in recent years with extensive government reforms in drug pricing, unpredictability around reimbursement and pricing decisions, and other structural changes. Despite these challenges, the Australian market still offers a number of opportunities for manufacturers.
This
Advertisement
Related to this article
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
2
Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somnivera
3
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
4
The Most Surprising Development in GLP-1s
5